Lava Therapeutics
About Lava Therapeutics
Lava Therapeutics is a company founded in 2016 by Erik van den Berg was acquired by XOMA Corporation in August 2025. It operates as a HealthTech. Lava Therapeutics has raised $101.83 million across 3 funding rounds from investors including XOMA Corporation, Sanofi Ventures and Pureos Bioventures. The company has 34 employees as of December 31, 2024. Lava Therapeutics offers products and services including Gammabody® Platform. Lava Therapeutics operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Hummingbird Bioscience, among others.
- Employees 34 as on 31 Dec, 2024
- Founders Erik van den Berg
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Lava Therapeutics N.V.
-
Annual Revenue
$11.98 M77.01as on Dec 31, 2024
-
Net Profit
$-25.11 M40.02as on Dec 31, 2024
-
EBITDA
$-29.22 M31.69as on Dec 31, 2024
-
Total Equity Funding
$101.83 M (USD)
in 3 rounds
-
Latest Funding Round
$83 M (USD), Series C
Sep 17, 2020
-
Investors
XOMA Corporation
& 10 more
-
Employee Count
34
as on Dec 31, 2024
-
Acquired by
XOMA Corporation
(Aug 04, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Lava Therapeutics
Lava Therapeutics is a publicly listed company on the NASDAQ with ticker symbol LVTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Lava Therapeutics
Lava Therapeutics offers a comprehensive portfolio of products and services, including Gammabody® Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Bispecific therapeutics are developed to engage gamma delta T cells.
Unlock access to complete
Unlock access to complete
Funding Insights of Lava Therapeutics
Lava Therapeutics has successfully raised a total of $101.83M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $83 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $83.0M
-
First Round
First Round
(23 May 2018)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Series C - Lava Therapeutics | Valuation | Sanofi Ventures , Pureos Bioventures |
|
| Jul, 2020 | Amount | Series A - Lava Therapeutics | Valuation |
investors |
|
| May, 2018 | Amount | Series A - Lava Therapeutics | Valuation | Gilde Healthcare , Versant Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Lava Therapeutics
Lava Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include XOMA Corporation, Sanofi Ventures and Pureos Bioventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Founded Year | Domain | Location | |
|
Venture capital is invested in innovative drug development companies.
|
Founded Year | Domain | Location | |
|
Ysios Capital is recognized as a leading life sciences investor.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Lava Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Lava Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Lava Therapeutics Comparisons
Competitors of Lava Therapeutics
Lava Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Hummingbird Bioscience, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| domain | founded_year | HQ Location |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Antibody drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Lava Therapeutics
Frequently Asked Questions about Lava Therapeutics
When was Lava Therapeutics founded?
Lava Therapeutics was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Who is the current CEO of Lava Therapeutics?
Stephen Hurly is the current CEO of Lava Therapeutics.
Is Lava Therapeutics a funded company?
Lava Therapeutics is a funded company, having raised a total of $101.83M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18.83M, raised on May 23, 2018.
How many employees does Lava Therapeutics have?
As of Dec 31, 2024, the latest employee count at Lava Therapeutics is 34.
What is the annual revenue of Lava Therapeutics?
Annual revenue of Lava Therapeutics is $11.98M as on Dec 31, 2024.
What does Lava Therapeutics do?
Lava Therapeutics is engaged in transforming cancer therapy through its proprietary Gammabody platform. This platform is utilized to create bispecific gamma delta T cell engager therapeutics, targeting a specific subset of T cells to fight cancer. The approach is designed to enhance natural tumor recognition, direct T cells to tumors, and selectively kill cancer cells while triggering immune responses. Solutions are developed for the healthcare sector, specifically in oncology, with preclinical studies showing promising results in tumor cell killing and immune activation. The potential for durable immune responses is emphasized as a key benefit for patient survival.
Who are the top competitors of Lava Therapeutics?
Lava Therapeutics's top competitors include Hummingbird Bioscience, Juno Therapeutics and Lyell Immunopharma.
What products or services does Lava Therapeutics offer?
Lava Therapeutics offers Gammabody® Platform.
Is Lava Therapeutics publicly traded?
Yes, Lava Therapeutics is publicly traded on NASDAQ under the ticker symbol LVTX.
Who are Lava Therapeutics's investors?
Lava Therapeutics has 11 investors. Key investors include XOMA Corporation, Sanofi Ventures, Pureos Bioventures, Redmile Group, and Ysios Capital.
What is Lava Therapeutics's ticker symbol?
The ticker symbol of Lava Therapeutics is LVTX on NASDAQ.